B+
Bull case
30%
Probability
Target price
$190.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
INSM
InsmedBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$140.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$100.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+79.3
Score
AI commentary
News tone is positive following the reported revenue growth and raised BRINSUPRI guidance, but social, options, short-interest, and employee-sentiment data are unavailable. The available post-print price snapshot remained near the $132.55 anchor, suggesting no confirmed durable repricing yet. Analyst target or estimate revisions after the print are unavailable, so the evidence supports monitoring rather than high-conviction directional positioning.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-06eventQ2 2026 results and raised BRINSUPRI guidanceHigh impact
Insmed reported Q2 revenue of $425.5 million, including BRINSUPRI revenue of $309.2 million, up 49% sequentially, and raised 2026 BRINSUPRI guidance to $1.25-$1.40 billion while reiterating ARIKAYCE guidance of $450-$470 million [#SEC-8K-2026-08-06]. A pre-release Zacks reference cited $389.72 million revenue; primary-source EPS comparison is unavailable [#PR-EARNINGS-2026-07-30].
2026-09-30catalystBRINSUPRI launch executionMedium impact
The immediate operating test is whether the 49% sequential BRINSUPRI growth rate and strong U.S. demand can support the raised 2026 revenue range without meaningful access, payer, or launch-friction deterioration [#SEC-8K-2026-08-06].
2027-08-08catalystARIKAYCE label-expansion pathwayHigh impact
Insmed plans an FDA supplemental application for ARIKAYCE in the second half of 2026 after positive Phase 3b ENCORE results, with parallel Japanese review potential [#SEC-8K-2026-05-07]. Submission progress and regulatory outcomes remain uncertain.
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology